Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SRDAN VERSTOVSEK and COURTNEY DINARDO.
SRDAN VERSTOVSEK
Connection Strength
3.302
COURTNEY DINARDO
  1. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61.
    View in: PubMed
    Score: 0.467
  2. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid. 2024 Jun; 3(6):EVIDoa2300362.
    View in: PubMed
    Score: 0.240
  3. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
    View in: PubMed
    Score: 0.198
  4. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164.
    View in: PubMed
    Score: 0.194
  5. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020 11 10; 4(21):5336-5342.
    View in: PubMed
    Score: 0.188
  6. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
    View in: PubMed
    Score: 0.185
  7. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866.
    View in: PubMed
    Score: 0.167
  8. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
    View in: PubMed
    Score: 0.165
  9. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
    View in: PubMed
    Score: 0.162
  10. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. 2024 07; 99(7):1434-1436.
    View in: PubMed
    Score: 0.059
  11. Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival. Br J Haematol. 2022 08; 198(3):604-608.
    View in: PubMed
    Score: 0.052
  12. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23.
    View in: PubMed
    Score: 0.051
  13. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.
    View in: PubMed
    Score: 0.050
  14. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
    View in: PubMed
    Score: 0.049
  15. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
    View in: PubMed
    Score: 0.049
  16. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.048
  17. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
    View in: PubMed
    Score: 0.048
  18. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
    View in: PubMed
    Score: 0.048
  19. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
    View in: PubMed
    Score: 0.046
  20. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.046
  21. Treating Leukemia in the Time of COVID-19. Acta Haematol. 2021; 144(2):132-145.
    View in: PubMed
    Score: 0.045
  22. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699.
    View in: PubMed
    Score: 0.045
  23. Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.
    View in: PubMed
    Score: 0.045
  24. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
    View in: PubMed
    Score: 0.045
  25. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.040
  26. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
    View in: PubMed
    Score: 0.040
  27. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.
    View in: PubMed
    Score: 0.039
  28. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.038
  29. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90.
    View in: PubMed
    Score: 0.038
  30. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.
    View in: PubMed
    Score: 0.037
  31. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060.
    View in: PubMed
    Score: 0.037
  32. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.
    View in: PubMed
    Score: 0.036
  33. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017 09; 31(9):1951-1961.
    View in: PubMed
    Score: 0.036
  34. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.
    View in: PubMed
    Score: 0.036
  35. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
    View in: PubMed
    Score: 0.036
  36. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
    View in: PubMed
    Score: 0.035
  37. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687.
    View in: PubMed
    Score: 0.035
  38. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):268-73.
    View in: PubMed
    Score: 0.033
  39. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62.
    View in: PubMed
    Score: 0.032
  40. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
    View in: PubMed
    Score: 0.031
  41. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.